Mucosal immunity following oral poliovirus vaccine and enhanced potency inactivated poliovirus vaccine immunization.

Efficacy and safety of oral poliovirus vaccine and inactivated poliovirus vaccine.

Affordable inactivated poliovirus vaccine: strategies and progress.

Impact of inactivated poliovirus vaccine on mucosal immunity: implications for the polio eradication endgame.

Use of inactivated or oral poliovirus vaccine in India.

Use of inactivated or oral poliovirus vaccine in India.

Potency of field samples of oral poliovirus vaccine.

Early immunization of neonates with trivalent oral poliovirus vaccine.

Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation.

Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: an open-label, randomised controlled trial.

Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs.

Immune response to intradermally injected inactivated poliovirus vaccine.

Intradermal inactivated poliovirus vaccine: a preclinical dose-finding study.

Immune response of infants to inactivated poliovirus vaccine injected intradermally.

Immunization in India with trivalent and monovalent oral poliovirus vaccines of enhanced potency.

Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use.

Switch from oral to inactivated poliovirus vaccine in Yogyakarta Province, Indonesia: summary of coverage, immunity, and environmental surveillance.

The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission.

Comprehensive screening for immunodeficiency-associated vaccine-derived poliovirus: an essential oral poliovirus vaccine cessation risk management strategy.

Modeling the dynamics of oral poliovirus vaccine cessation.

Use of oral poliovirus vaccine for unlicensed indications.

Immunogenicity and effectiveness of routine immunization with 1 or 2 doses of inactivated poliovirus vaccine: systematic review and meta-analysis.

Estimating the likely coverage of inactivated poliovirus vaccine in routine immunization: evidence from demographic and health surveys.

National choices related to inactivated poliovirus vaccine, innovation and the endgame of global polio eradication.

Safety of diphtheria, tetanus, acellular pertussis and inactivated poliovirus (DTaP-IPV) vaccine.

Suggest Documents

Efficacy and safety of oral poliovirus vaccine and inactivated poliovirus vaccine.

Affordable inactivated poliovirus vaccine: strategies and progress.

Impact of inactivated poliovirus vaccine on mucosal immunity: implications for the polio eradication endgame.

Use of inactivated or oral poliovirus vaccine in India.

Use of inactivated or oral poliovirus vaccine in India.

Potency of field samples of oral poliovirus vaccine.

Early immunization of neonates with trivalent oral poliovirus vaccine.

Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation.

Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: an open-label, randomised controlled trial.

Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs.

Immune response to intradermally injected inactivated poliovirus vaccine.

Intradermal inactivated poliovirus vaccine: a preclinical dose-finding study.

Immune response of infants to inactivated poliovirus vaccine injected intradermally.

Immunization in India with trivalent and monovalent oral poliovirus vaccines of enhanced potency.

Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use.

Switch from oral to inactivated poliovirus vaccine in Yogyakarta Province, Indonesia: summary of coverage, immunity, and environmental surveillance.

The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission.

Comprehensive screening for immunodeficiency-associated vaccine-derived poliovirus: an essential oral poliovirus vaccine cessation risk management strategy.

Modeling the dynamics of oral poliovirus vaccine cessation.

Use of oral poliovirus vaccine for unlicensed indications.

Immunogenicity and effectiveness of routine immunization with 1 or 2 doses of inactivated poliovirus vaccine: systematic review and meta-analysis.

Estimating the likely coverage of inactivated poliovirus vaccine in routine immunization: evidence from demographic and health surveys.

National choices related to inactivated poliovirus vaccine, innovation and the endgame of global polio eradication.

Safety of diphtheria, tetanus, acellular pertussis and inactivated poliovirus (DTaP-IPV) vaccine.

Mucosal immunity following oral poliovirus vaccine and enhanced potency inactivated poliovirus vaccine immunization.

Recommend Documents

Follow Us